scholarly journals Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe)

BMJ Open ◽  
2017 ◽  
Vol 7 (9) ◽  
pp. e016606 ◽  
Author(s):  
Christel Häggström ◽  
Fredrik Liedberg ◽  
Oskar Hagberg ◽  
Firas Aljabery ◽  
Viveka Ströck ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Data Base ◽  
Cancer Survival ◽  
Urinary Bladder Cancer ◽  
Remote Access ◽  
National Register ◽  
Cancer Data ◽  
Muscle Invasive

PurposeTo monitor the quality of bladder cancer care, the Swedish National Register of Urinary Bladder Cancer (SNRUBC) was initiated in 1997. During 2015, in order to study trends in incidence, effects of treatment and survival of men and women with bladder cancer, we linked the SNRUBC to other national healthcare and demographic registers and constructed the Bladder Cancer Data Base Sweden (BladderBaSe).ParticipantsThe SNRUBC is a nationwide register with detailed information on 97% of bladder cancer cases in Sweden as compared with the Swedish Cancer Register. Participants in the SNRUBC have registered data on tumour characteristics at diagnosis, and for 98% of these treatment data have been captured. From 2009, the SNRUBC holds data on 88% of eligible participants for follow-up 5 years after diagnosis of non-muscle invasive bladder cancer, and from 2011, data on surgery details and complications for 85% of participants treated with radical cystectomy. The BladderBaSe includes all data in the SNRUBC from 1997 to 2014, and additional covariates and follow-up data from linked national register sources on comorbidity, socioeconomic factors, detailed information on readmissions and treatment side effects, and causes of death.Findings to dateStudies based on data in the SNRUBC have shown inequalities in survival and treatment indication by gender, regions and hospital volume. The BladderBaSe includes 38 658 participants registered in SNRUBC with bladder cancer diagnosed from 1 January 1997 to 31 December 2014. The BladderBaSe initiators are currently in collaboration with researchers from the SNRUBC investigating different aspects of bladder cancer survival.Future plansThe SNRUBC and the BladderBaSe project are open for collaborations with national and international research teams. Collaborators can submit proposals for studies and study files can be uploaded to servers for remote access and analysis. For more information, please contact the corresponding author.

scholarly journals Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe)

2020 ◽  
Vol 126 (5) ◽  
pp. 625-632
Author(s):  
Firas Aljabery ◽  
Fredrik Liedberg ◽  
Christel Häggström ◽  
Viveka Ströck ◽  
Abolfazl Hosseini ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Data Base ◽  
Urinary Bladder Cancer ◽  
Population Based ◽  
Population Based Study ◽  
Cancer Data

scholarly journals Combination role of DAPK methylation in urinary sediment and B ultrasound in evaluating follow-up of urinary bladder cancer

2020 ◽  
Author(s):  
Linlin Wang ◽  
Fuquan Jiang ◽  
Changfeng Li ◽  
Jiansong Han
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
High Performance ◽  
Urinary Bladder Cancer ◽  
Youden Index ◽  
Urinary Sediment ◽  
Negative Results ◽  
Kappa Test

Abstract Background: Urinary bladder cancer (UBC) is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. This paper aims to explore the combination role of DAPK methylation in urinary sediment and B ultrasound in diagnosing recurrent UBC. Methods: A total of 1021 cases of primary UBC undergone electrocision of bladder tumor through urethra were included and were subjected to follow up every 3 month within 2 years. B ultrasound, DAPK methylation in urinary sediment, examination of exfoliated cells in urine and cystoscopy were performed during the follow up. The data recorded in follow up were subjected to chi-square test and Kappa test. ROC was drawn to evaluate the diagnostic role of each parameter in recurrent UBC. Results: Among the 1021 patients, 115 patients were found with recurrent UBC by cystoscopy and biopsy two years after the operation, and failed to complete the follow up, thus the effective number of follow up was 906. The cystoscopy results were not only consistent with that of B ultrasound (Kappa = 0.785, P < 0.05), but also agreed with that of DAPK methylation in urinary sediment and combination of B ultrasound with DAPK methylation (Kappa = 0.517, P < 0.05, Kappa = 0.593, P < 0.05). ROC curve indicated that the area under curve of combination of B ultrasound with DAPK methylation was 0.922 (sensitivity, 92.86%; specificity, 91.63%; Youden index, 0.845) with negative prediction value of 99.4% which suggested that the recurrent risk would be low in case negative results were obtained. Conclusion: Those data supported that combination of DAPK methylation with B ultrasound has high performance in diagnosing recurrent UBC.

Serum Paraoxonase-1 Concentration as a Potential Predictor of Urinary Bladder Cancer Recurrence. A Five Year Follow-Up Study

2018 ◽  
Vol 49 (2) ◽  
pp. 119-122 ◽  
Author(s):  
Simona Iftimie ◽  
Anabel García-Heredia ◽  
Francesc Pujol-Bosch ◽  
Antoni Pont-Salvadó ◽  
Ana Felisa López-Azcona ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Cancer Recurrence ◽  
Urinary Bladder Cancer ◽  
Paraoxonase 1 ◽  
Potential Predictor ◽  
Follow Up Study ◽  
Serum Paraoxonase ◽  
Bladder Cancer Recurrence

scholarly journals Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

2019 ◽  
Vol 20 (6) ◽  
pp. 1291 ◽  
Author(s):  
Aikaterini Giannopoulou ◽  
Athanassios Velentzas ◽  
Eumorphia Konstantakou ◽  
Margaritis Avgeris ◽  
Stamatia Katarachia ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Histone Deacetylases ◽  
Strong Association ◽  
Hdac Inhibitors ◽  
Urinary Bladder Cancer ◽  
Molecular Heterogeneity ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Muscle Invasive

Urinary bladder cancer is a common malignancy, being characterized by substantial patient mortality and management cost. Its high somatic-mutation frequency and molecular heterogeneity usually renders tumors refractory to the applied regimens. Hitherto, methotrexate-vinblastine-adriamycin-cisplatin and gemcitabine-cisplatin represent the backbone of systemic chemotherapy. However, despite the initial chemosensitivity, the majority of treated patients will eventually develop chemoresistance, which severely reduces their survival expectancy. Since chromatin regulation genes are more frequently mutated in muscle-invasive bladder cancer, as compared to other epithelial tumors, targeted therapies against chromatin aberrations in chemoresistant clones may prove beneficial for the disease. “Acetyl-chromatin” homeostasis is regulated by the opposing functions of histone acetyltransferases (HATs) and histone deacetylases (HDACs). The HDAC/SIRT (super-)family contains 18 members, which are divided in five classes, with each family member being differentially expressed in normal urinary bladder tissues. Since a strong association between irregular HDAC expression/activity and tumorigenesis has been previously demonstrated, we herein attempt to review the accumulated published evidences that implicate HDACs/SIRTs as critical regulators in urothelial bladder cancer. Moreover, the most extensively investigated HDAC inhibitors (HDACis) are also analyzed, and the respective clinical trials are also described. Interestingly, it seems that HDACis should be preferably used in drug-combination therapeutic schemes, including radiation.

Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base

2014 ◽  
Vol 114 (5) ◽  
pp. 719-726 ◽  
Author(s):  
Angela B. Smith ◽  
Allison M. Deal ◽  
Michael E. Woods ◽  
Eric M. Wallen ◽  
Raj S. Pruthi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Data Base ◽  
National Cancer Data Base ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Cancer Data ◽  
Muscle Invasive

scholarly journals Survival of patients with urinary bladder cancer in Jordan, 2005–2014

2021 ◽  
Vol 27 (07) ◽  
pp. 648-655
Author(s):  
Nour Abdo ◽  
Majd Alsoukhni ◽  
Anwar Batieha ◽  
Kamal Arqoub
Keyword(s):  
Overall Survival ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
National Level ◽  
Urinary Bladder Cancer ◽  
Developed Countries ◽  
Cancer Data ◽  
Factors Associated ◽  
Survival Probabilities ◽  
Significant Difference

Background: Urinary bladder cancer is the fourth most common cancer in Jordan. No research on survival from bladder cancer at the national level has been conducted before. Aims: This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify factors associated with survival. Methods: Data were obtained from the database of the Jordan cancer registry. All cases of urinary bladder cancer in Jordanians registered during 2005–2014 were included in the study (n = 2139). Data collected for each case included: age, sex, date of diagnosis, and stage and grade at diagnosis. Actuarial life table survival analysis was used to determine the overall survival probabilities. Cox proportional hazard regression was used to identify independent factors associated with survival. Results: The overall 1-, 3-, 5- and 10-year survival probabilities for urinary bladder cancer were 85%, 73%, 69% and 59%, respectively (standard error = 0.01 for each). No significant difference in survival probabilities was found between males and females (P = 0.642). The overall survival probabilities decreased significantly as age at diagnosis increased (P < 0.005). Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. Conclusions: The survival of patients with bladder cancer in Jordan is comparable to that reported from developed countries. A high percentage of data was missing and the reporting of some variables was inconsistent. To improve the quality of cancer data, regular training is needed for hospital focal points on recording complete data

scholarly journals Squamous Cell Carcinoma of the Urinary Bladder: Clinicopathological and Molecular Update

2021 ◽  
Author(s):  
Sunil Vitthalrao Jagtap ◽  
Swati S Jagtap ◽  
Parneet Kaur ◽  
Snigdha Vartak
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Urinary Bladder Cancer ◽  
Cell Phenotype ◽  
Molecular Features ◽  
Muscle Invasive

Urinary bladder cancer is one of the most prevalent cancers worldwide.Squamous Cell Carcinoma (SCC) is an uncommon subtype of urinary bladder carcinoma.It is a malignant epithelial neoplasm arising in the urinary bladder demonstrating a pure squamous cell phenotype. On histopathology it is considered when tumor is showing pure squamous morphology without any component of conventional urothelial carcinoma. The SCC is a histologically distinct form of cancer. It arises from the uncontrolled multiplication of cells showing particular cytological or tissue architectural characteristics of squamous cell differentiation, such as the presence of keratin, tonofilament bundles or desmosomes. Majority of bladder SCC are high grade, high stage tumors with most cancers having muscle invasion at the time of diagnosis while overall about 80% of bladder cancers are non-muscle invasive bladder cancer at diagnosis.COX-2 is markedly expressed in all SCCs. An increased COX-2 level induces the development of SCC of the bladder affecting many biological features of this tissue including apoptosis, cell adhesion, angiogenesis and invasiveness.TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma suggesting a common tumorgenesis and potential utility as a molecular urine-based-screening assay.This review summarizes the current features related to clinical , pathological, and molecular features of SCC of urinary bladder.

Sign in / Sign up

Export Citation Format

Share Document